Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women

Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02910817

Enrollment

102

Registered

2016-09-22

Start date

2015-01-31

Completion date

2016-12-31

Last updated

2017-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Brief summary

RCT to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.

Interventions

DRUGMetformin

The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.

OTHERPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* The inclusion criteria restricted the patients to 39 years old with basal FSH \< 10 IU/ml and normal TSH and prolacin.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Total number of retrieved oocytes	Two weeks Metformin treatment

Secondary

Measure	Time frame
Live birth rate	End of the pregnancy

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026